BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Policy

  FDA Sets Adcomm for BMS, J&J CAR T Therapies Amid Class-Wide Safety Concerns

  The FDA’s Oncologic Drugs Advisory Committee will meet on March 15 to discuss BMS and J&J applications for their CAR T-cell therapies Abecma and Carvykti, respectively.

  February 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Regeneron Looks to Target Weight Loss Market with Muscle-Preserving Antibodies

  The biotech is taking a synergistic approach to obesity with two muscle-preserving antibodies set to enter a Phase II study in mid-2024 in combination with existing incretin-based treatments.

  February 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Career Advice

  Academia vs. Industry: Differences in Workplace Culture

  Academic and industry jobs are distinguished by their approaches to collaboration and exploratory research, among other factors.

  February 5, 2024

   · 

  5 min read

   · 

  Sanjukta Mondal
• 

  Drug Development

  Amgen’s Weight-Loss Drug Candidate Shows Promise in Early Data

  Phase I results published Monday suggest Amgen’s investigational weight-loss drug MariTide produces longer-lasting effects than GLP-1s currently on the market.

  February 5, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• 

  Deals

  Novo Holdings Buys CDMO Catalent for $16.5B to Boost Semaglutide Supply

  The investment arm of the Novo Nordisk Foundation is acquiring contract development and manufacturing organization Catalent to help meet high demand for Ozempic and Wegovy.

  February 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  4DMT’s Experimental Gene Therapy Cuts Eylea Use in Phase II Wet AMD Trial

  Topline results from a mid-stage study show that 4D Molecular Therapeutics’ investigational gene therapy cut annual rates of Eylea injections by 85% and 89% for the low and high doses, respectively.

  February 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Genome Editing Biotech Metagenomi Targets IPO to Raise $86.9M

  Metagenomi could potentially raise over $100 million if the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $16 per share.

  February 5, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• Drug Development

  TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March

  TauRx Pharmaceuticals Ltd. announced that the company will present the 24-month data from its Phase III LUCIDITY trial of hydromethylthionine mesylate at the upcoming AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference from 5-9 March 2024, in Lisbon, Portugal.

  February 5, 2024

   · 

  4 min read
• Hitachi High-Tech America, Inc. and Nabsys to collaborate through a “Rapid Application to Market Penetration User Partnership” Program to advance the OhmX Electronic Genome Mapping Platform

  The collaboration aims to continue to gain commercial traction after Nabsys announced the OhmX platform in October 2023.

  February 5, 2024

   · 

  3 min read
• Biotech Beach

  Vektor Medical Secures $16 Million Series A Funding

  Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced a $16 million Series A investment co-led by Solas BioVentures and TVM Capital Life Science.

  February 5, 2024

   · 

  4 min read